BioCentury
ARTICLE | Strategy

Round 1 to Affymetrix in Incyte bout

September 13, 1999 7:00 AM UTC

Affymetrix Inc. received a boost in its battle with Incyte Pharmaceuticals Inc. over microarray technology, as the U.S. Patent and Trademark Office last week ruled in favor of AFFX in a patent interference proceeding requested by INCY. Nevertheless, whether AFFX will be able to prevent INCY from marketing its gene expression microarray (GEM) technology will have to await the outcome of a lawsuit in the U.S. District Court for the Northern District of California.

The PTO upheld AFFX's U.S. Patent No. 5,744,305 covering arrays of nucleic acids with greater than 400 probes per square centimeter and No. 5,800,992 covering two-color hybridization assays for gene expression analysis (see BioCentury, April 19). ...